Profluent and Lilly teamed up on AI‑designed enzymes in a deal worth up to $2.25B. Big tech, bigger gene edits.
Serif Biomedicines has emerged from stealth mode to continue developing “modified DNA,” a new class of therapeutics designed ...
Scientists have uncovered an unexpected way cells can generate cancer-driving proteins—by cutting RNA into shorter, functional fragments rather than following the standard blueprint.
Profluent, which will design recombinases for the collaboration, could receive up to $2.25 billion in the deal.
Recent advances in genomics, genome editing, and imaging technologies have revealed that neural activity can rapidly alter chromatin accessibility, ...
DNAWORKS’ world premiere production of “The Secret Sharer" centers queer joy while SpeakEasy Stage Company’s “Swept Away” is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results